Cargando…

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008

This analysis describes the epidemiology and outcomes of invasive candidiasis caused by non-albicans species of Candida in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance) registry from 2004 to 2008. A total of 2,496 patients with non-albicans species of Candida isola...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pfaller, Michael A., Andes, David R., Diekema, Daniel J., Horn, David L., Reboli, Annette C., Rotstein, Coleman, Franks, Billy, Azie, Nkechi E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4081561/ https://www.ncbi.nlm.nih.gov/pubmed/24991967 http://dx.doi.org/10.1371/journal.pone.0101510

Ejemplares similares

Genome-Wide Scan for Linkage to Type 1 Diabetes in 2,496 Multiplex Families From the Type 1 Diabetes Genetics Consortium
por: Concannon, Patrick, et al.
Publicado: (2009)

Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome
por: Reboli, Annette C, et al.
Publicado: (2011)

P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

466. All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study
por: Marukutira, Tafireyi, et al.
Publicado: (2014)

Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species
por: Ou, Huang-Tz, et al.
Publicado: (2017)

Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: Support for the 2009 IDSA treatment guidelines for candidiasis
por: Kett, Daniel H, et al.
Publicado: (2011)

PM496. How delusion is formed?
por: Kim, Hee Jun, et al.
Publicado: (2016)

Molecular association of Candida albicans and vulvovaginal candidiasis: focusing on a solution
por: David, Helma, et al.
Publicado: (2023)

PB2496: CAR-T CELLS THERAPY COMBINED WITH POMALIDOMIDE AGAINST RELAPSE AND REFRACTORY MM OR ALL WITH EXTRAMEDULLARY INVOLVEMENT
por: Zhao, Jie, et al.
Publicado: (2023)

Low prevalence of antifungal resistant Candida africana, in the C. albicans complex causing vulvovaginal candidiasis
por: Farahyar, Shirin, et al.
Publicado: (2020)

Genotyping, antifungal susceptibility, enzymatic activity, and phenotypic variation in Candida albicans from esophageal candidiasis
por: Jafarian, Hadis, et al.
Publicado: (2021)

In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model
por: Lepak, Alexander J, et al.
Publicado: (2017)

2496. Hepatitis C Virus Among Inpatients in the Direct-acting Antiviral Era: Prevalence, Linkage to Care, Treatment Disparities, and Comorbidity Burden
por: Forrister, Nicholas, et al.
Publicado: (2023)

2496: Improving minority health and reducing health disparities: Research at the intersection of health disparity science and clinical and translational science
por: Sufian, Meryl, et al.
Publicado: (2018)

Molecular Identification and Antifungal Susceptibility Pattern of Non-albicans Candida Species Isolated from Vulvovaginal Candidiasis
por: Nejat, Ziba Abbasi, et al.
Publicado: (2018)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Mucosal Bacteria Modulate Candida albicans Virulence in Oropharyngeal Candidiasis
por: Bertolini, M., et al.
Publicado: (2021)

Cation Transporters of Candida albicans—New Targets to Fight Candidiasis?
por: Volkova, Marina, et al.
Publicado: (2021)

496. Carbapenem-resistant Enterobacter: A Case-Case–Control Investigation
por: Cohen Mendel, Leore, et al.
Publicado: (2019)

Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis
por: Pfaller, Michael A.
Publicado: (2015)

Genetic diversity and antifungal susceptibility of Candida albicans isolates from Iranian HIV-infected patients with oral candidiasis
por: Tamai, Iradj Ashrafi, et al.
Publicado: (2021)

202 Antifungal Stewardship: The Clinician's Perspective on Barriers to Implementation
por: Safdar, Amar, et al.
Publicado: (2014)

Acciones de calidad, 2004-2008.
Publicado: (2008)

Frequency of Candidiasis and Colonization of Candida albicans in Relation to Oral Contraceptive Pills
por: Aminzadeh, Atousa, et al.
Publicado: (2016)

Neutrophils From Patients With Invasive Candidiasis Are Inhibited by Candida albicans Biofilms
por: Kernien, John F., et al.
Publicado: (2020)

Glycogen Metabolism in Candida albicans Impacts Fitness and Virulence during Vulvovaginal and Invasive Candidiasis
por: Miao, Jian, et al.
Publicado: (2023)

SUN-496 A Challenging Diagnosis of Thyrotoxic Periodic Paralysis
por: Mroueh, Gabriela, et al.
Publicado: (2020)

SAT496 Tobacco Smoking May Mimic Subclinical Hyperthyroidism
por: Alshantti, Raeda, et al.
Publicado: (2023)

Candidiasis and Mechanisms of Antifungal Resistance
por: Bhattacharya, Somanon, et al.
Publicado: (2020)

Overdiagnosis and overtreatment of nipple and breast candidiasis: A review of the relationship between diagnoses of mammary candidiasis and Candida albicans in breastfeeding women
por: Douglas, Pamela
Publicado: (2021)

The YMCA/Steps Community Collaboratives, 2004-2008
por: Jones, Ellen S., et al.
Publicado: (2009)

Plesiomonas shigelloides Infection, Ecuador, 2004–2008
por: Escobar, Juan C., et al.
Publicado: (2012)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Recognition of Candida albicans and Role of Innate Type 17 Immunity in Oral Candidiasis
por: Pavlova, Anna, et al.
Publicado: (2020)

Streptococcus mutans Secreted Products Inhibit Candida albicans Induced Oral Candidiasis
por: dos Santos, Jéssica Diane, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_di2ql0tsglgf5fee7rtj90ndpp